RYTM Nasdaq

Rhythm Pharmaceuticals, Inc.

RYTM A | $40.08 0.2% 160K

(0.0% 1d) (0.9% 1m) (89.1% 1y) (0.0% 2d) (2.5% 3d) (5.0% 7d) (5.98% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 2,410,431,040
http://www.rhythmtx.com
Sec Filling | Patents | 70 employees

(US) Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

gastrointestinal car-t genetic mc4r agonist treatment

add to watch list Paper trade email alert is off

Press-releases

Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
RYTM A | $40.08 0.2% 160K

Health Technology

| 3.84% | O: 1.51% H: 0.0% C: -1.66%
pharmaceuticals grants

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
RYTM A | $40.08 0.2% 160K

Health Technology

| -5.46% | O: -0.02% H: 1.11% C: 0.9%
million pharmaceuticals

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
RYTM A | $40.08 0.2% 160K

Health Technology

| -1.36% | O: -0.37% H: 1.71% C: -1.86%
rm-718 first agonist pharmaceuticals trial

Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Published: 2024-03-11 (Crawled : 20:00) - globenewswire.com
RYTM A | $40.08 0.2% 160K

Health Technology

| -1.26% | O: 0.57% H: 2.87% C: -1.37%
pharmaceuticals grants

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
RYTM A | $40.08 0.2% 160K

Health Technology

| -2.68% | O: 1.61% H: 1.68% C: -0.22%
pharmaceuticals

Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
Published: 2024-02-22 (Crawled : 12:00) - globenewswire.com
RYTM A | $40.08 0.2% 160K

Health Technology

| -18.05% | O: 0.39% H: 1.08% C: -10.08%
obesity japan setmelanotide pharmaceuticals

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
Published: 2024-02-22 (Crawled : 12:00) - globenewswire.com
RYTM A | $40.08 0.2% 160K

Health Technology

| -18.05% | O: 0.39% H: 1.08% C: -10.08%
business update pharmaceuticals financial

Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Published: 2024-02-08 (Crawled : 21:00) - globenewswire.com
RYTM A | $40.08 0.2% 160K

Health Technology

| -15.88% | O: 1.01% H: 7.6% C: 6.56%
pharmaceuticals grants

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
Published: 2024-02-07 (Crawled : 13:00) - globenewswire.com
RYTM A | $40.08 0.2% 160K

Health Technology

| -16.04% | O: 0.25% H: 2.05% C: 0.06%
imcivree obesity control positive italy treatment pharmaceuticals

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
RYTM A | $40.08 0.2% 160K

Health Technology

| -12.57% | O: 0.11% H: 2.58% C: -3.69%
report year pharmaceuticals financial results

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001104659-24-047957	4	2024-04-17	2024-04-15	Buy	A	10000	10000
0001104659-24-047957	4	2024-04-17	2024-04-15	Buy	A	8905	8905
0001104659-24-047957	4	2024-04-17	2024-04-15	Sell	D	2031	0
0001104659-24-047957	4	2024-04-17	2024-04-14	Sell	M	10375	31125
0001104659-24-047957	4	2024-04-17	2024-04-14	Sell	M	10375	34870
0001104659-24-037927	4	2024-03-22	2024-03-21	Sell	S	18235	30